资料显示，津药达仁堂集团股份有限公司位于天津市南开区白堤路17号，成立日期1981年12月29日，上市日期2001年6月6日，公司主营业务涉及药材种植、中药材贸易、中成药研发生产及销 达仁堂所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中盘、基因测序、融资融券、养老产业、高派息等。 截至6月30日，达仁堂股东户数5.45万，较上期增加4.24%；人均流通股10397股，较上期减少4.07%。2025年1月-6月，达仁堂实现营业收入26.51亿元，同比减少33.15%；归母净利润19 分红方面，达仁堂A股上市后累计派现51.17亿元。近三年，累计派现28.34亿元。 机构持仓方面，截止2025年6月30日，达仁堂十大流通股东中，香港中央结算有限公司位居第九大流通股东，持股446.24万股，相比上期增加26.43万股。南方中证500ETF（510500）位居第 责任编辑：小浪快报 8月22日，达仁堂盘中上涨2.03%，截至10:07，报47.16元/股，成交1.92亿元，换手率0.73%，总市值363.18亿元。 资金流向方面，主力资金净流入479.74万元，特大单买入1247.43万元，占比6.5 ...

Core Viewpoint - The company, Jiangxin Home, is experiencing growth driven by its focus on smart home products and its expansion into the health and wellness sector, benefiting from the depreciation of the RMB and its significant overseas revenue. Company Overview - Jiangxin Home is engaged in the research, design, production, and sales of smart electric sofas and beds, with its main products including single chairs, combination sofas, mechanisms, motors, and control devices [2][7]. - The company was established on May 31, 2002, and went public on September 13, 2021. Its main business revenue composition is 76.73% from smart electric sofas, 13.56% from smart electric beds, 8.84% from accessories, and 0.86% from other sources [7]. Financial Performance - For the first quarter of 2025, Jiangxin Home achieved a revenue of 773 million yuan, representing a year-on-year growth of 38.16%, and a net profit attributable to shareholders of 194 million yuan, up 60.41% year-on-year [7]. - The company has distributed a total of 519 million yuan in dividends since its A-share listing, with 423 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a significant overseas revenue share of 99.49%, benefiting from the depreciation of the RMB [2]. - Jiangxin Home is advancing into the health and wellness industry with products such as smart beds for rehabilitation and home care [3]. Shareholder and Institutional Holdings - As of March 31, 2025, Jiangxin Home had 5,493 shareholders, with an increase of 0.90% from the previous period. The average number of circulating shares per person rose by 160.31% [7]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and several new entrants among the top ten circulating shareholders [9]. Technical Analysis - The average trading cost of the stock is 64.36 yuan, with the stock price approaching a resistance level of 95.00 yuan, indicating potential for upward movement if this level is surpassed [6]. Capital Flow Analysis - The stock experienced a net inflow of 243,700 yuan today, with no significant trends in major capital movements observed [4][5].